stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) EV/FCF
As of 5 November 2026, Insulet Corporation (PODD) trades at a EV/FCF of 48.0×. Over the past ten years it has ranged from −1,183× (November 2020) to 2,571× (December 2015); the current reading is higher than 79% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 57.8× | (8.53%) |
| FY2024 | 63.2× | (84.92%) |
| FY2023 | 419× | — |
| FY2022 | −538× | — |
| FY2021 | −96.9× | — |
| FY2020 | −202× | — |
| FY2019 | −150× | — |
| FY2018 | −38.5× | — |
| FY2017 | −128× | — |
| FY2016 | −354× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 40.7× | (1.53%) |
| Jun 2026 | 41.3× | 5.64% |
| Mar 2026 | 39.1× | (32.41%) |
| Dec 2025 | 57.8× | 7.17% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 8.3× |
| GMED Globus Medical, Inc. compare | 14.9× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.8× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 29.5× |
| BRKR Bruker Corporation compare | 38.8× |
| PODD Insulet Corporation | 48.0× |
| TXG 10x Genomics compare | 58.9× |
| PEN Penumbra, Inc. compare | 59.8× |
| GKOS Glaukos Corporation compare | 360× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement